PDA

View Full Version : Multiple Sclerosis Research

Pages : [1] 2
  1. Hauben, et al. (2001): Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease
  2. Ousman & David (2001): Myelin loss in adult spinal cord and the role of immune cells
  3. Ruffini, et al. (2001): Fibroblast growth factor-II gene therapy reverts the clinical course and the pathological signs of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice
  4. Kotter, et al. (2001): Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination
  5. Murray, et al. (2001): Spontaneous remyelination following extensive demyelination is associated with improved neurological function in a viral model of multiple sclerosis
  6. Sobel (2001): The extracellular matrix in multiple sclerosis: an update
  7. Silber & Sharief (1999): Axonal degeneration in the pathogenesis of multiple sclerosis
  8. Hurko & Walsh (2000): Novel drug development for amyotrophic lateral sclerosis
  9. Poser & Brinar (2001): Diagnostic criteria for multiple sclerosis
  10. Rowland (1999): Six important themes in amyotrophic lateral sclerosis (ALS) research, 1999
  11. Willison & O'Hanlon (1999): The immunopathogenesis of Miller Fisher syndrome
  12. Kiefer, et al. (2001): The role of macrophages in immune-mediated damage to the peripheral nervous system
  13. Link, et al. (2001): Vaccination with autologous dendritic cells: from experimental autoimmune encephalomyelitis to multiple sclerosis
  14. Oksenberg, et al. (2001): Multiple sclerosis: Genomic rewards
  15. Jaeckel, et al. (2001). Treatment of Acute Hepatitis C with Interferon Alfa-2b
  16. Leussink, et al. (2001). High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes
  17. Balcer (2001). Optic Neuritis.
  18. Richert, et al. (2001). Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis
  19. Rumalla, et al. (2001). The effects of glucocorticoid therapy on inflammatory responses to coronary artery bypass graft surgery
  20. Steinmetz, et al. (2001). Hospital-at-home as a solution for the treatment requirements of acute exacerbation in multiple sclerosis
  21. Tashima, et al. (2001). Susac's syndrome: beneficial effects of corticosteroid therapy in a Japanese case
  22. Grauer, et al. (2001). Glucocorticoid therapy of multiple sclerosis.
  23. Schmidt, et al. (2001). Interferon-beta treatment of experimental autoimmune encephalomyelitis leads to rapid nonapoptotic termination of T cell infiltration
  24. Losseff, et al. (2001). T1 hypointensity of the spinal cord in multiple sclerosis
  25. Sobel (2001). The extracellular matrix in multiple sclerosis: an update
  26. Ziemssen, et al. (2001). Risk-Benefit Assessment of Glatiramer Acetate in Multiple Sclerosis
  27. Fraser, et al. (2001). Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis
  28. Sela & Teitelbaum (2001). Glatiramer acetate in the treatment of multiple sclerosis
  29. Filippi, et al. (2001). Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes"
  30. Rovaris, et al. (2001). Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications.
  31. Francis (2001). Glatiramer acetate (Copaxone)
  32. Khan, et al. (2001). A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis
  33. Kietz, et al. (2002). Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period
  34. ten Hove, et al. (2002). Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease
  35. Noonan, et al. (2002). Prevalence estimates for MS in the United States and evidence of an increasing trend for women
  36. Rammohan, et al. (2002). Efficacy and safety of modafinil (Provigil((R))) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study
  37. New Study Shows Medical Patch for M.S. Fatigue Effective
  38. Lankford (2002). A quantitative morphometric analysis of rat spinal cord remyelination following transplantation of allogenic Schwann cells
  39. Wolswijk G (2002). Oligodendrocyte precursor cells in the demyelinated multiple sclerosis spinal cord
  40. Chang, et al. (2002). Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis
  41. Chari & Blakemore (2002). Efficient recolonisation of progenitor-depleted areas of the CNS by adult oligodendrocyte progenitor cells.
  42. Calza, et al. (2002). Thyroid hormone activates oligodendrocyte precursors and increases a myelin-forming protein and NGF content in the spinal cord during experimental allergic encephalomyelitis
  43. Bieber, et al. (2002). Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice
  44. Gregori, et al. (2002). The tripotential glial-restricted precursor (GRP) cell and glial development in the spinal cord: generation of bipotential oligodendrocyte-type-2 astrocyte progenitor cells and dorsal-ventral differences in GRP cell function
  45. Hand, et al. (2002). A novel locus for familial amyotrophic lateral sclerosis, on chromosome 18q.
  46. Fu, et al. (2002). Dual origin of spinal oligodendrocyte progenitors and evidence for the cooperative role of Olig2 and Nkx2.2 in the control of oligodendrocyte differentiation
  47. Higgins, et al. (2002). Mutant Cu, Zn Superoxide Dismutase that Causes Motoneuron Degeneration Is Present in Mitochondria in the CNS
  48. Jones, et al. (2002). Pathological CNS Autoimmune Disease Triggered by Traumatic Spinal Cord Injury: Implications for Autoimmune Vaccine Therapy
  49. Garbuzova-Davis, et al. (2002). Positive Effect of Transplantation of hNT Neurons (NTera 2/D1 Cell-Line) in a Model of Familial Amyotrophic Lateral Sclerosis
  50. Bonilla, et al. (2002). Haematopoietic progenitor cells from adult bone marrow differentiate into cells that express oligodendroglial antigens in the neonatal mouse brain
  51. Sim, et al. (2002). The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation
  52. Gratwohl, et al. (2001). Stem cell transplantation for autoimmune diseases
  53. Oyama, et al. (2002). Engraftment syndrome: a common cause for rash and fever following autologous hematopoietic stem cell transplantation for multiple sclerosis
  54. AAN Meeting: Spinal cord injury Abstracts Apr 13-20, Denver, CO
  55. AAN Meeting: Multiple Sclerosis Abstracts (Apr 13-20, Denver)
  56. Kenney, et al. (2002). A Double-Blind, Placebo-Controlled, Modified Crossover Pilot Study of the Effects of Ginkgo Biloba on Cognitive and Functional Abilities in Multiple Sclerosis
  57. Wingerchuk, et al. (2002). Aspirin for Multiple Sclerosis-Related Fatigue: Results of a Double-Blind Placebo-Controlled Study
  58. Waubant, et al. (2002). Serum Levels of MMP-9 and TIMP-1 Predict MRI Activity in Patients with Secondary Progressive MS and Interferon Therapy Shifts MMP-9/TIMP-1 towards Normal
  59. Dalton, et al. (2002). Natalizumab Treatment for Relapsing MS: Further Results of a Randomized, Double-Blind, Placebo-Controlled Trial
  60. Sharief, et al. (2002). Evidence of Dose Response: Effects of Two Interferon Beta-1a Products on Relapse-Related Parameters in Multiple Sclerosis
  61. Jeffery, et al. (2002). Safety and Efficacy of Combination Therapy with Interferon Beta-1b and Mitoxantrone in Worsening Multiple Sclerosis Using Monthly Gadolinium Enhanced MRI
  62. Miller, et al. (2002). Efficacy of Sildenafil Citrate in Men with Erectile Dysfunction and Multiple Sclerosis: Results of an Open-Label Study
  63. BBC News - Stem Cells help MS patients
  64. Bateman & Goldish (2002). Autonomic dysreflexia in multiple sclerosis.
  65. Plumb, et al. (2002). bnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis
  66. Ure & Rodriguez (2002). Preservation of neurologic function during inflammatory demyelination correlates with axon sparing in a mouse model of multiple sclerosis.
  67. Dhib-Jalbut (2002). Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis.
  68. Schwid, et al. (2002). Quantitative functional measures in MS: what is a reliable change?
  69. Killestein, et al. (2002). Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial
  70. Meuller, et al. (2002). Birth outcomes and need for hospitalization after delivery among women with multiple sclerosis.
  71. Bonilla, et al. (2002). Haematopoietic progenitor cells from adult bone marrow differentiate into cells that express oligodendroglial antigens in the neonatal mouse brain.
  72. Makhlouf, et al. (2002). Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol)
  73. Calabresi, et al. (2002). An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS
  74. Maron, et al. (2002). Oral tolerance to copolymer 1 in myelin basic protein (MBP) TCR transgenic mice: cross-reactivity with MBP-specific TCR and differential induction of anti-inflammatory cytokines.
  75. Popovic, et al. (2002). Inhibition of autoimmune encephalomyelitis by a tetracycline.
  76. Murray, et al. (2002). Cellular sources and targets of IFN-gamma-mediated protection against viral demyelination and neurological deficits.
  77. Morris, et al. (2002). Changes in gait and fatigue from morning to afternoon in people with multiple sclerosis.
  78. Miller, et al. (2002). Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis.
  79. De Stefano, et al. (2001). Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability
  80. Cathespin S Inihibitor Suppresses MS PLEASE MOVE TO MS
  81. Abdul-Majid (2002). Fc receptors are critical for autoimmune inflammatory damage to the central nervous system in experimental autoimmune encephalomyelitis.
  82. Abedin, et al. (2002). Oxidative DNA damage in the spinal cord in multiple sclerosis.
  83. Achiron & Faibel (2002). Sandlike appearance of Virchow-Robin spaces in early multiple sclerosis: a novel neuroradiologic marker.
  84. Aharoni, et al. (2002) Oral treatment of mice with copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 cells in the central nervous system.
  85. Marchioni, et al. (200).
  86. Maron, et al. (2002). Oral tolerance to copolymer 1 in myelin basic protein (MBP) TCR transgenic mice: cross-reactivity with MBP-specific TCR and differential induction of anti-inflammatory cytokines.
  87. Marrosu, et al. (2002). Patients with multiple sclerosis and risk of type 1 diabetes mellitus in Sardinia, Italy: a cohort study.
  88. Marrosu, et al. (2002). Genetic factors and the founder effect explain familial MS in Sardinia.
  89. O'Leary, et al. (2002). Increasing local levels of IGF-I mRNA expression using adenoviral vectors does not alter oligodendrocyte remyelination in the CNS of aged rats.
  90. Blakemore, et al. (2002). Modelling large areas of demyelination in the rat reveals the potential and possible limitations of transplanted glial cells for remyelination in the CNS.
  91. Adalbert, et al. (2002). DL-Homocysteic acid application disrupts calcium homeostasis and induces degeneration of spinal motor neurons in vivo.
  92. Filipovic, et al. (2002). Expression of Golli proteins in adult human brain and multiple sclerosis lesions.
  93. du Haut Champ (2002). Treatment of autoimmune diseases by ablating autoimmune lymphoid clones and transplantation of allogeneic or autologous hematopoietic stem cells
  94. Blakemore, et al. (2002). Modelling large areas of demyelination in the rat reveals the potential and possible limitations of transplanted glial cells for remyelination in the CNS.
  95. Lehnardt, et al. (2002). The toll-like receptor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS.
  96. Sim, et al. (2002). The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation.
  97. Myers (2001). Immunologic therapy for secondary and primary progressive multiple sclerosis.
  98. Bonilla, et al. (2002). Haematopoietic progenitor cells from adult bone marrow differentiate into cells that express oligodendroglial antigens in the neonatal mouse brain.
  99. Chari & Blakemore (2002). Efficient recolonisation of progenitor-depleted areas of the CNS by adult oligodendrocyte progenitor cells.
  100. Calza, et al. (2002). Thyroid hormone activates oligodendrocyte precursors and increases a myelin-forming protein and NGF content in the spinal cord during experimental allergic encephalomyelitis.
  101. Khan, et al. (2002). Comparative Assessment of Immunomodulating Therapies for Relapsing-Remitting Multiple Sclerosis.
  102. Zhong, et al. (2002). Multiantigen/multiepitope-directed immune-specific suppression of "complex autoimmune encephalomyelitis" by a novel protein product of a synthetic gene.
  103. Durelli & Isoardo (2002). High-dose intravenous immunoglobulin treatment of multiple sclerosis.
  104. Marchetti, et al. (2002). Exposure to a dysfunctional glucocorticoid receptor from early embryonic life programs the resistance to experimental autoimmune encephalomyelitis via nitric oxide-induced immunosuppression
  105. Harlan & Winn (2002). Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy.
  106. Kozak & Rychlik (2002). Developments in hematopoietic stem-cell transplantation in the treatment of autoimmune diseases.
  107. einer & Cohen (2002). Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects.
  108. Robinson, et al. (2002). Millennium Award. Proteomics for the development of DNA tolerizing vaccines to treat autoimmune disease.
  109. Besnier, et al. (2002). Extracorporeal photochemotherapy for secondary chronic progressive multiple sclerosis: a pilot study.
  110. Limone, et al. (2002). Hypothalamic-pituitary-adrenal axis function and cytokine production in multiple sclerosis with or without interferon-beta treatment.
  111. Melo, et al. (2002). Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases.
  112. Coyle, et al. (2002). Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response.
  113. Martinez-Caceres, et al. (2002). Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects.
  114. Farina, et al. (2002). Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients.
  115. Wiesemann, et al. (2002). Interferon-beta increases the stimulatory capacity of monocyte-derived dendritic cells to induce IL-13, IL-5 and IL-10 in autologous T-cells.
  116. Neville, et al. (2002). Myelin-specific tolerance attenuates the progression of a virus-induced demyelinating disease: implications for the treatment of MS.
  117. Heinzerling, et al. (2002). Panniculitis after subcutaneous injection of interferon beta in a multiple sclerosis patient
  118. Chartier-Kastler, et al. (2002). Neurogenic bladder management and cutaneous non-continent ileal conduit.
  119. Lorenzi & Ford (2002). Multiple sclerosis and pregnancy.
  120. Thoumie & Mevellec (2002). Relation between walking speed and muscle strength is affected by somatosensory loss in multiple sclerosis.
  121. Pozzilli, et al. (2002). Home based management in multiple sclerosis: results of a randomised controlled trial.
  122. Wade, et al. (2002). A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis.
  123. Monzani, et al. (2002). iscordant Effect of IFN-beta1a Therapy on Anti-IFN Antibodies and Thyroid Disease Development in Patients with Multiple Sclerosis.
  124. Pertwee (2002). Cannabinoids and multiple sclerosis.
  125. Makar, et al. (2002). IFN-beta Gene Transfer into the Central Nervous System Using Bone Marrow Cells as a Delivery System.
  126. Emerson, et al. (2002). Activation of histamine H2 receptors ameliorates experimental allergic encephalomyelitis.
  127. Sumelaht, et al. (2002). Survival of multiple sclerosis in Finland between 1964 and 1993.
  128. Minocycline - Any preliminary results
  129. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS
  130. Early onset multiple sclerosis
  131. Whitehead, et al. (2002). Determinants of the interaction of the spinal muscular atrophy disease protein SMN with the dimethylarginine-modified Box H/ACA snoRNP protein GAR1.
  132. Immunomodulatory Agents for the Treatment of Relapsing Multiple Sclerosis
  133. Correlates of disability in multiple sclerosis detected by transcranial magnetic stimulation
  134. Eight-year follow-up study of brain atrophy in patients with MS
  135. A randomized, double-blind, dose-comparison study of weekly interferon ß-1a in relapsing MS
  136. Mighty Mice Are Less Susceptible to Muscular Dystrophy Gene's Effects
  137. No Connection between Gulf War, Veterans' Neuromuscular Symptoms
  138. Jellinger (2002). Vascular-ischemic dementia: an update.
  139. Paolillo, et al. (2002). A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta.
  140. Lewanska, et al. (2002). No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment.
  141. Sorensen, et al. (2002). Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis.
  142. Delalande, et al. (2002). Late onset multiple sclerosis
  143. Scott (2002). Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors.
  144. Hanson & Cafruny (2002). Current concepts in multiple sclerosis: Part II.
  145. Lings (2002). The influence of medical conditions on the ability to drive
  146. Killestein, et al. (2002). Baseline T cell reactivity in multiple sclerosis is correlated to efficacy of interferon-beta.
  147. Seidi, et al. (2002). Expression of CD5 on B lymphocytes correlates with disease activity in patients with multiple sclerosis.
  148. Brettschneider, et al. (2002). The macrophage activity marker sCD14 is increased in patients with multiple sclerosis and upregulated by interferon beta-1b.
  149. Wang, et al. (2002). Chemokine receptors associated with immunity within and outside the central nervous system in early relapsing-remitting multiple sclerosis.
  150. Barth, et al. (2002). Analysis of immunoregulatory T-helper cell subsets in patients with multiple sclerosis: relapsing-progressive course correlates with enhanced T(H1), relapsing-remitting course with enhanced T(H0) reactivity.
  151. Fainardi, et al. (2002). Clinical and MRI disease activity in multiple sclerosis are associated with reciprocal fluctuations in serum and cerebrospinal fluid levels of soluble HLA class I molecules.
  152. van Seventer, et al. (2002). Interferon-beta differentially regulates expression of the IL-12 family members p35, p40, p19 and EBI3 in activated human dendritic cells.
  153. Skurkovich, et al. (2002). Anticytokine therapy - new approach to the treatment of autoimmune and cytokine-disturbance diseases.
  154. Tong, et al. (2002). Frontal fluency and memory functioning among multiple sclerosis patients in Hong Kong.
  155. Nelson & Paulson (2002). Idiopathic Parkinson's disease(s) may follow subclinical episodes of perivenous demyelination.
  156. Slade, et al. (2002). A randomised controlled trial to determine the effect of intensity of therapy upon length of stay in a neurological rehabilitation setting.
  157. Jarrett, et al. (2002). Managing severe lower limb spasticity in multiple sclerosis: does intrathecal phenol have a role?
  158. Chen, et al. (2002). The Type IV Phosphodiesterase Inhibitor Rolipram Induces Expression of the Cell Cycle Inhibitors p21(Cip1) and p27(Kip1), Resulting in Growth Inhibition, Increased Differentiation, and Subsequent Apoptosis of Malignant A-l72 Gl
  159. Fassas (2002). Autologous stem cell transplants in treatment of multiple sclerosis: where we stand and future prospects.
  160. Pender & Wolfe (2002). Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects.
  161. White, et al. (2002). Isolation and growth of a cytopathic agent from multiple sclerosis brain tissue.
  162. Weiner & Cohen (2002). Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects.
  163. Weilbach & Toyka (2002). Does Down's syndrome protect against multiple sclerosis?
  164. Waxman (2002). Sodium channels as molecular targets in multiple sclerosis.
  165. Walters, et al. (2002). nhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis.
  166. Voskuhl (2002). Gender issues and multiple sclerosis.
  167. Voltz, et al. (2002). Multiple sclerosis. Therapeutic nihilism is the wrong approach here
  168. Vollmer, et al. (2002). Disability and treatment patterns of multiple sclerosis patients in United States: a comparison of veterans and nonveterans.
  169. Villoslada, et al. (2002). The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-beta.
  170. Villar, et al. (2002). Intrathecal IgM synthesis in neurologic diseases: relationship with disability in MS.
  171. Villar, et al. (2002). Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS.
  172. Vermersch, et al. (2002). Interferon beta1a (Avonex) treatment in multiple sclerosis: similarity of effect on progression of disability in patients with mild and moderate disability.
  173. Vermersch, et al. (2002). Quality of life in multiple sclerosis: influence of interferon-beta1 a (Avonex) treatment.
  174. Verdun, et al. (2002). Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?
  175. Vandenbroeck, et al. (2002). Chromosome 7q21-22 and multiple sclerosis: evidence for a genetic susceptibility effect in vicinity to the protachykinin-1 gene.
  176. van Veen, et al. (2002). The FAS-670 polymorphism influences susceptibility to multiple sclerosis.
  177. Van Houdenhove, et al. (2002). Daily hassles reported by chronic fatigue syndrome and fibromyalgia patients in tertiary care: a controlled quantitative and qualitative study.
  178. van der Meijs, et al. (2002). Incidence of enhancement of the trigeminal nerve on MRI in patients with multiple sclerosis.
  179. Urushitani, et al. (2002). roteasomal inhibition by misfolded mutant superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic lateral sclerosis.
  180. Ure & Rodriguez (2002). Preservation of neurologic function during inflammatory demyelination correlates with axon sparing in a mouse model of multiple sclerosis.
  181. Ure & Rodriguez (2002). Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease.
  182. Uitdehaag, et al. (2002). Multiple sclerosis functional composite: impact of reference population and interpretation of changes.
  183. Trottier, et al. (2002). Enhanced detection of Theiler's virus RNA copy equivalents in the mouse central nervous system by real-time RT-PCR.
  184. Giuliani, et al. (2002). Age-related disability in multiple sclerosis.
  185. Tremlett, et al. (2002). Asthma and multiple sclerosis: an inverse association in a case-control general practice population.
  186. Totolian, et al. (2002). Multiple sclerosis with childhood onset
  187. Torrey (2002). Studies of individuals with schizophrenia never treated with antipsychotic medications: a review.
  188. Toncev, et al. (2002). Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction.
  189. Toncev, et al. (2002). High-dose methylprednisolone therapy in multiple sclerosis increases serum uric acid levels.
  190. Tokuda, et al. (2002). Prednisolone (30-60 mg/day) for diseases other than AD decreases amyloid beta-peptides in CSF.
  191. Tirapu-Ustarroz, et al. (2002). Executive functions: the need for the integration of concepts
  192. Thoumie & Meveller (2002). Relation between walking speed and muscle strength is affected by somatosensory loss in multiple sclerosis.
  193. Thornton, et al. (2002). Memory in multiple sclerosis: contextual encoding deficits.
  194. Tarrats, et al. (2002). Varicella, ephemeral breastfeeding and eczema as risk factors for multiple sclerosis in Mexicans
  195. Zwibel (2002). The cost of delaying treatment in multiple sclerosis: what is lost is not regained.
  196. Ziemssen, et al. (2002). Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor.
  197. Zifko, et al. (2002). Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study.
  198. CHAMPS (2002). MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group.
  199. Conference synopsis: hematopoietic stem cell therapy in autoimmune diseases, October 2001.
  200. MS, Parkinson's disease and physiotherapy.
  201. Abraham & Yun (2002). Laryngopharyngeal dysmotility in multiple sclerosis.
  202. Aharoni, et al. (2002). Oral treatment of mice with copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 cells in the central nervous system.
  203. Allanson, et al. (2002). Characteristics of patients with persistent severe disability and medically unexplained neurological symptoms: a pilot study.
  204. Alvarez Cerme (2002). nitial axonal lesion in multiple sclerosis. Reasons for early treatment
  205. Amato, et al. (2002). The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy.
  206. Andersson, et al. (2002). ultiple MAG peptides are recognized by circulating T and B lymphocytes in polyneuropathy and multiple sclerosis.
  207. Araki, et al. (2002). Relationship between urinary symptoms and disease-related parameters in multiple sclerosis.
  208. Arciniegas & Anderson (2002). Suicide in Neurologic Illness.
  209. Ardissone, et al. (2002). Effects of high doses of corticosteroids on bone metabolism.
  210. Aron (2002). Hepatitis B vaccine and multiple sclerosis.
  211. Aslam & Singh (2002). Aplastic Anemia Associated With Interferon beta-1a.
  212. Aupperle, et al. (2002). Three screening batteries to detect cognitive impairment in multiple sclerosis.
  213. Bach (2002). Current concepts of autoimmunity
  214. Bagert, et al. (2002). Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management.
  215. Baraczka, et al. (2002). Immunoserological changes in the cerebro-spinal fluid and serum in systemic lupus erythematosus patients with demyelinating syndrome and multiple sclerosis.
  216. Barak & Achiron (2002). Effect of interferon-beta-1b on cognitive functions in multiple sclerosis.
  217. Barcellos, et al. (2002). Genetic basis for clinical expression in multiple sclerosis.
  218. Barkhof & Scheltens (2002). Imaging of white matter lesions.
  219. Basu, et al. (2002). The type 1 interleukin-1 receptor is essential for the efficient activation of microglia and the induction of multiple proinflammatory mediators in response to brain injury.
  220. Baumhackl (2002). Prevalence of multiple sclerosis in Austria. Results of a nationwide survey.
  221. Beck, et al. (2002). Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.
  222. Benedict, et al. (2002). Frontal cortex atrophy predicts cognitive impairment in multiple sclerosis.
  223. Bergers, et al. (2002). Diffuse signal abnormalities in the spinal cord in multiple sclerosis: direct postmortem in situ magnetic resonance imaging correlated with in vitro high-resolution magnetic resonance imaging and histopathology.
  224. Berk, et al. (2002). Thalamic deep brain stimulation for the treatment of tremor due to multiple sclerosis: a prospective study of tremor and quality of life.
  225. Bertolotto, et al. (2002). Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.
  226. Besler, et al. (2002). Serum levels of antioxidant vitamins and lipid peroxidation in multiple sclerosis.
  227. Besnier, et al. (2002). Extracorporeal photochemotherapy for secondary chronic progressive multiple sclerosis: a pilot study.
  228. Bitsch & Bruck (2002). ifferentiation of multiple sclerosis subtypes: implications for treatment.
  229. Blakemore, et al. (2002). Modelling large areas of demyelination in the rat reveals the potential and possible limitations of transplanted glial cells for remyelination in the CNS.
  230. Boiko, et al. (2002). Early onset multiple sclerosis: a longitudinal study.
  231. Boiko, et al. (2002). Association and linkage of juvenile MS with HLA-DR2(15) in Russians.
  232. Bozzali, et al. (2002). Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging.
  233. Brassat, et al. (2002). Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS.
  234. Brola, et al. (2002). Effect of variable magnetic field on motor impairment and quality of life in patients with multiple sclerosis
  235. Brundula, et al. (2002). Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis.
  236. Brunmark, et al. (2002). The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis.
  237. Bruno, et al. (2002). Multiple sclerosis candidate autoantigens except myelin oligodendrocyte glycoprotein are transcribed in human thymus.
  238. Butzkueven, et al. (2002). LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival.
  239. Marracci, et al. (2002). Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis.
  240. Baumann (2003). Haematopoietic stem cell transplantation in 12 patients with cerebral X-linked adrenoleukodystrophy.
  241. Fredrikson, et al. (2003). Elevated Suicide Risk among Patients with Multiple Sclerosis in Sweden.
  242. Nayak, et al. (2003). Use of unconventional therapies by individuals with multiple sclerosis.
  243. Evidence of early cortical atrophy in MS
  244. Epstein-Barr virus may increase risk of multiple sclerosis
  245. del Aguila, et al. (2003). Prognosis in amyotrophic lateral sclerosis: a population-based study.
  246. Stuifbergen, et al. (2003). A randomized clinical trial of a wellness intervention for women with multiple sclerosis.
  247. Mycko, et al. (2003). cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity.
  248. Ganor, et al. (2003). Human T Cells Express a Functional Ionotropic Glutamate Receptor GluR3, and Glutamate by Itself Triggers Integrin-Mediated Adhesion to Laminin and Fibronectin and Chemotactic Migration.
  249. Okafor (2003). Thalidomide for erythema nodosum leprosum and other applications.
  250. Lendvay & Marshall (2003). The Tuberous Sclerosis Complex and its Highly Variable Manifestations.